577 research outputs found

    Optimising magnetic sentinel lymph node biopsy in an in vivo porcine model

    Get PDF
    The magnetic technique for sentinel lymph node biopsy (SLNB) has been evaluated in several clinical trials. An in vivo porcine model was developed to optimise the magnetic technique by evaluating the effect of differing volume, concentration and time of injection of magnetic tracer. A total of 60 sentinel node procedures were undertaken. There was a significant correlation between magnetometer counts and iron content of excised sentinel lymph nodes (SLNs) (r = 0.82; P < 0.001). Total number of SLNs increased with increasing volumes of magnetic tracer (P < 0.001). Transcutaneous magnetometer counts increased with increasing time from injection of magnetic tracer (P < 0.0001), plateauing within 60 min. Increasing concentration resulted in higher iron content of SLNs (P = 0.006). Increasing magnetic tracer volume and injecting prior to surgery improve transcutaneous ‘hotspot’ identification but very high volumes, increase the number of nodes excised. From the Clinical Editor Sentinel lymph node biopsy (SLNB) is the standard of care for axillary staging of breast cancer patients. Although the current gold standard technique is the combined injection of technetium-labelled nanocolloid and blue dye into the breast, the magnetic technique, using superparamagnetic carboxydextran-coated iron oxide (SPIO), has also been demonstrated as a feasible alternative. In this article, the authors set up to study factors in order to optimize the magnetic tracers. Graphical abstract Variable volumes and concentrations of a magnetic tracer were injected into the third inguinal mammary gland bilaterally in an in vivo porcine model (1) allowing the performance of magnetic sentinel lymph node biopsy of draining inguinal nodes (2). The harvested nodes were ‘darkly stained’ for iron uptake and ‘hot’ for magnetometer counts (3). The iron was deposited within the cortex and subcapsular space – visible as blue using PERL’s staining – on histopathology (4) and was quantified using quantitative magnetometry and a validated iron-grading scale

    Persoonlijk leiderschap

    Get PDF
    Brandon Pouw (26 jaar) is werkzaam als beleidsmedewerker Bestuurlijk Zaken bij de provincie Zuid-Holland. Geboren Utrechter, nu woont hij samen met zijn vriendin in Leiden. Hij studeerde Politicologie in Nijmegen, Grenoble en Leiden en werd in januari verkozen tot Jonge Ambtenaar van het Jaar. Voor vragen over de column kun je gerust een mailtje sturen naar [email protected]

    Ex vivo magnetic sentinel lymph node detection in colorectal cancer with a SPIO tracer

    Get PDF
    A new method for selecting sentinel lymph nodes (SNs) in colorectal cancer tissue was investigated in 12 patients. A tracer consisting of superparamagnetic ironoxide (SPIO) nanoparticles was injected in the resected tissue. A handheld magnetic probe was used to select SNs to which the SPIO was drained. Vibrating sample magnetometry was performed on the lymph nodes to quantify the amount of SPIO in the nodes. High-field MRI allowed to depict the distribution of SPIO in the node, and revealed small anatomical structures. One or more SPIO containing nodes were successfully selected with the magnetic probe in all 12 patients

    Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

    Get PDF
    Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA). Investigation to identify predictive tools of bDMARD response is a highly active and prolific area of research. In addition to clinical phenotyping, cellular and molecular characterisation of synovial tissue and blood in patients with RA, using different technologies, can facilitate predictive testing. This narrative review will summarise the literature for the available bDMARD classes and focus on where progress has been made. We will also look ahead and consider the increasing use of ‘omics’ technologies, the potential they hold as well as the challenges, and what is needed in the future to fully realise our ambition of personalised bDMARD treatment
    corecore